Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for AML and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IDH2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IDH2 WT / Mutant (R140Q, R172K) Protein High purity (>95%), Theoretical MW. Sequence Verified. |
View IDH2 Products |
| Gene Delivery | IDH2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IDH2 Products |
| Benchmark Ab | Anti-IDH2 Benchmark Antibody Recombinant positive control for western blot and ELISA. |
View IDH2 Products |
| Validator | IDH2 siRNA Set For knockdown verification. |
View IDH2 Products |
| Related Target A | IDH1 Crucial for parallel screening of pan-IDH inhibitors or compensating resistance pathways. |
View IDH1 Products |
| Related Target B | FLT3 High-frequency co-mutation target in AML for combination therapy studies. |
View FLT3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. WT Selectivity Screening | IDH2 WT, R140Q, and R172K recombinant proteins available with >95% purity for rigorous counter-screening. |
| Enzymatic Assay Stability | Native folding preserved, Endotoxin <1EU/ug, ensuring consistent baseline in alpha-KG to 2-HG conversion assays. |
| Lack of Controls | Clinical Benchmark Antibodies included for precise assay standardization. |
| False Positives in Cellular Models | Sequence-verified siRNA included for target-specificity checks and validation of off-target toxicity. |
Live IDH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IDH2 therapeutics is intensifying, with major players shifting focus from traditional monotherapies to combination regimens and next-generation pan-mutant small molecule inhibitors. As first-generation therapies like Enasidenib reach the clinic and establish efficacy in relapsed/refractory Acute Myeloid Leukemia (AML), the next wave of R&D is targeting acquired clinical resistance (such as second-site Q316E and I319M mutations) and expanding into solid tumors like gliomas, cholangiocarcinoma, and chondrosarcoma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Mutant Selective) | Agios / Servier, Celgene | R/R AML, MDS | Selectivity Assay (Need High-Purity WT and Mutant Proteins) |
| Small Molecule (Pan-IDH1/2) | Forma Therapeutics, Bayer | Glioma, Solid Tumors | Cross-Target Validation (Need both IDH1 and IDH2 orthologs) |
| Targeted Protein Degradation (PROTAC) | Various Biotechs | Refractory AML | Ternary Complex Formation (Need functionally active structural proteins) |
| Combination Therapy | AbbVie (with Venetoclax) | Newly Diagnosed AML | Cellular Phenotypic Screening (Need Stable Cell Lines via Lentivirus) |